(Q36542313)

14 August 2017

1 reference

title

Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications (English)

1 reference

14 August 2017

1 reference

Fabrizio Stocchi

3

0 references

Charles Warren Olanow

series ordinal

1

object named as

C Warren Olanow

1 reference

14 August 2017

Jose A Obeso

2

1 reference

14 August 2017

1 August 2006

1 reference

14 August 2017

1 reference

14 August 2017

5

1 reference

14 August 2017

677-687

1 reference

14 August 2017

8

1 reference

Parkinson's disease. First of two parts

14 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970521-X

7 January 2021

The scientific basis for the current treatment of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970521-X

7 January 2021

Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970521-X

7 January 2021

The control of firing pattern in nigral dopamine neurons: single spike firing

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970521-X

7 January 2021

Effects of L-dopa on extracellular dopamine in striatum of normal and 6-hydroxydopamine-treated rats

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970521-X

7 January 2021

Real-time decoding of dopamine concentration changes in the caudate?putamen during tonic and phasic firing

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970521-X

7 January 2021

The role of pulsatile versus continuous dopamine receptor stimulation for functional recovery in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970521-X

7 January 2021

Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, Part I

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970521-X

7 January 2021

Success and problems of long-term levodopa therapy in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970521-X

7 January 2021

Young-onset Parkinson's disease: a clinical review

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970521-X

7 January 2021

Antiparkinsonian activity and dyskinesia risk of ropinirole and L-DOPA combination therapy in drug naïve MPTP-lesioned common marmosets (Callithrix jacchus).

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970521-X

7 January 2021

Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970521-X

7 January 2021

The functional anatomy of basal ganglia disorders

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970521-X

7 January 2021

Primate models of movement disorders of basal ganglia origin

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970521-X

7 January 2021

Anatomy of the dopamine system in the basal ganglia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970521-X

7 January 2021

Predictive reward signal of dopamine neurons

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970521-X

7 January 2021

Afferent modulation of dopamine neuron firing differentially regulates tonic and phasic dopamine transmission

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970521-X

7 January 2021

The nigrostriatal pathway in the rat: A single-axon study of the relationship between dorsal and ventral tier nigral neurons and the striosome/matrix striatal compartments.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970521-X

7 January 2021

Anatomical substrates for glutamate-dopamine interactions: evidence for specificity of connections and extrasynaptic actions

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970521-X

7 January 2021

Pathophysiology of the basal ganglia in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970521-X

7 January 2021

How is firing activity of substantia nigra cells regulated? Relevance of pattern-code in the basal ganglia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970521-X

7 January 2021

Opposing effects of striatonigral feedback pathways on midbrain dopamine cell activity.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970521-X

7 January 2021

Electrophysiological interactions between striatal glutamatergic and dopaminergic systems

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970521-X

7 January 2021

Direct receptor cross-talk can mediate the modulation of excitatory and inhibitory neurotransmission by dopamine

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970521-X

7 January 2021

Dopamine modulates release from corticostriatal terminals.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970521-X

7 January 2021

D1 receptor activation enhances evoked discharge in neostriatal medium spiny neurons by modulating an L-type Ca2+ conductance.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970521-X

7 January 2021

Dopaminergic modulation of glutamate release in striatum as measured by microdialysis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970521-X

7 January 2021

Opposite influences of endogenous dopamine D1 and D2 receptor activation on activity states and electrophysiological properties of striatal neurons: studies combining in vivo intracellular recordings and reverse microdialysis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970521-X

7 January 2021

Tonic D2-mediated attenuation of cortical excitation in nucleus accumbens neurons recorded in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970521-X

7 January 2021

Dopamine receptor subtypes selectively modulate excitatory afferents from the hippocampus and amygdala to rat nucleus accumbens neurons

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970521-X

7 January 2021

Quantification of the dopamine innervation in adult rat neostriatum.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970521-X

7 January 2021

Dopaminergic Modulation of Axon Collaterals Interconnecting Spiny Neurons of the Rat Striatum

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970521-X

7 January 2021

The striatofugal fiber system in primates: a reevaluation of its organization based on single-axon tracing studies

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970521-X

7 January 2021

GABAergic circuits of the striatum.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970521-X

7 January 2021

Dopamine-mediated regulation of striatal neuronal and network interactions

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970521-X

7 January 2021

Dopamine and cAMP-regulated phosphoprotein 32 kDa controls both striatal long-term depression and long-term potentiation, opposing forms of synaptic plasticity

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970521-X

7 January 2021

Endogenous nicotinic cholinergic activity regulates dopamine release in the striatum

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970521-X

7 January 2021

Unilateral dopamine denervation blocks corticostriatal LTP

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970521-X

7 January 2021

Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970521-X

7 January 2021

Firing regulation in dopaminergic cells: effect of the partial degeneration of nigrostriatal system in surviving neurons

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970521-X

7 January 2021

Evidence of a breakdown of corticostriatal connections in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970521-X

7 January 2021

Dendritic degeneration in neostriatal medium spiny neurons in Parkinson disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970521-X

7 January 2021

Selective elimination of glutamatergic synapses on striatopallidal neurons in Parkinson disease models.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970521-X

7 January 2021

Do compensatory processes underlie the preclinical phase of neurodegenerative disease? Insights from an animal model of parkinsonism

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970521-X

7 January 2021

Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970521-X

7 January 2021

Responses of pallidal neurons to striatal stimulation in monkeys with MPTP-induced parkinsonism

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970521-X

7 January 2021

Abnormal influences of passive limb movement on the activity of globus pallidus neurons in parkinsonian monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970521-X

7 January 2021

Neurons in the globus pallidus do not show correlated activity in the normal monkey, but phase-locked oscillations appear in the MPTP model of parkinsonism

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970521-X

7 January 2021

Firing patterns and correlations of spontaneous discharge of pallidal neurons in the normal and the tremulous 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine vervet model of parkinsonism.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970521-X

7 January 2021

Dynamics of tremor-related oscillations in the human globus pallidus: a single case study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970521-X

7 January 2021

High-frequency Synchronization of Neuronal Activity in the Subthalamic Nucleus of Parkinsonian Patients with Limb Tremor

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970521-X

7 January 2021

Physiological aspects of information processing in the basal ganglia of normal and parkinsonian primates

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970521-X

7 January 2021

Role of high-affinity dopamine uptake and impulse activity in the appearance of extracellular dopamine in striatum after administration of exogenous L-DOPA: studies in intact and 6-hydroxydopamine-treated rats.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970521-X

7 January 2021

Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970521-X

7 January 2021

Internal globus pallidus discharge is nearly suppressed during levodopa-induced dyskinesias

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970521-X

7 January 2021

Effects of apomorphine on globus pallidus neurons in parkinsonian patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970521-X

7 January 2021

Apomorphine induces changes in GPi spontaneous outflow in patients with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970521-X

7 January 2021

Dopamine replacement therapy reverses abnormal synchronization of pallidal neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine primate model of parkinsonism.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970521-X

7 January 2021

A critical interaction between NR2B and MAGUK in L-DOPA induced dyskinesia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970521-X

7 January 2021

Chronic treatment with L-DOPA, but not bromocriptine induces dyskinesia in MPTP-parkinsonian monkeys. Correlation with [3H]spiperone binding.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970521-X

7 January 2021

De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970521-X

7 January 2021

Cabergoline, a long-acting dopamine D2-like receptor agonist, produces a sustained antiparkinsonian effect with transient dyskinesias in parkinsonian drug-naive primates.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970521-X

7 January 2021

Continuous dopaminergic stimulation reduces risk of motor complications in parkinsonian primates

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970521-X

7 January 2021

L-dopa induces dyskinesia in normal monkeys: behavioural and pharmacokinetic observations

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970521-X

7 January 2021

Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): seven cases

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970521-X

7 January 2021

Parkin disease: a phenotypic study of a large case series

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970521-X

7 January 2021

Preproenkephalin mRNA expression in the caudate-putamen of MPTP monkeys after chronic treatment with the D2 agonist U91356A in continuous or intermittent mode of administration: comparison with L-DOPA therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970521-X

7 January 2021

Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970521-X

7 January 2021

Changes in the regional and compartmental distribution of FosB- and JunB-like immunoreactivity induced in the dopamine-denervated rat striatum by acute or chronic L-dopa treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970521-X

7 January 2021

Relevance of the MPTP primate model in the study of dyskinesia priming mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970521-X

7 January 2021

ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970521-X

7 January 2021

Increase of preproenkephalin mRNA levels in the putamen of Parkinson disease patients with levodopa-induced dyskinesias

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970521-X

7 January 2021

Dopamine agonist-induced dyskinesias are correlated to both firing pattern and frequency alterations of pallidal neurones in the MPTP-treated monkey

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970521-X

7 January 2021

Dopamine dependency of oscillations between subthalamic nucleus and pallidum in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970521-X

7 January 2021

Continuous and intermittent levodopa differentially affect basal ganglia function

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970521-X

7 January 2021

Continuous and intermittent levodopa differentially affect rotation induced by D-1 and D-2 dopamine agonists

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970521-X

7 January 2021

Levodopa replacement therapy alters enzyme activities in striatum and neuropeptide content in striatal output regions of 6-hydroxydopamine lesioned rats

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970521-X

7 January 2021

A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970521-X

7 January 2021

Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970521-X

7 January 2021

Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970521-X

7 January 2021

Agonists vs levodopa in PD: the thrilla of whitha

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970521-X

7 January 2021

Continuous dopamine-receptor stimulation in advanced Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970521-X

7 January 2021

Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970521-X

7 January 2021

An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970521-X

7 January 2021

Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease. A multicenter 5-year study. The CR First Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970521-X

7 January 2021

Intravenous boluses and continuous infusions ofL-DOPA methyl ester in fluctuating patients with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970521-X

7 January 2021

Safety, tolerability, and efficacy of continuous transdermal dopaminergic stimulation with rotigotine patch in early-stage idiopathic Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970521-X

7 January 2021

Long-term duodenal infusion of levodopa for motor fluctuations in parkinsonism

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970521-X

7 January 2021

JEJUNAL DELIVERY OF LEVODOPA METHYL ESTER

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970521-X

7 January 2021

Duodenal delivery of levodopa for on-off fluctuations in parkinsonism: preliminary observations.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970521-X

7 January 2021

Double-blind, placebo-controlled, crossover study of duodenal infusion of levodopa/carbidopa in Parkinson's disease patients with 'on-off' fluctuations.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970521-X

7 January 2021

A 10-year follow-up--genotypic analysis disproves phenotypic classification

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970521-X

7 January 2021

Long-term intraduodenal infusion of a water based levodopa-carbidopa dispersion in very advanced Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970521-X

7 January 2021

Ten years' experience with enteral levodopa infusions for motor fluctuations in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970521-X

7 January 2021

Intermittent vs Continuous Levodopa Administration in Patients With Advanced Parkinson Disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970521-X

7 January 2021

Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970521-X

7 January 2021

COMT inhibitors in Parkinson's disease: can they prevent and/or reverse levodopa-induced motor complications?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970521-X

7 January 2021

Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug-naive primates

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970521-X

7 January 2021

Effect of pulsatile administration of levodopa on dyskinesia induction in drug‐naïve MPTP‐treated common marmosets: Effect of dose, frequency of administration, and brain exposure

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970521-X

7 January 2021

Dopaminergic responsiveness to apomorphine after chronic treatment with subcutaneous lisuride infusion in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970521-X

7 January 2021

Induction by dopamine D1 receptor agonist ABT-431 of dyskinesia similar to levodopa in patients with Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970521-X

7 January 2021

Nasogastric and intravenous infusions of (+)-4-propyl-9-hydroxynaphthoxazine (PHNO) in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970521-X

7 January 2021

N-0923, a novel soluble dopamine D2 agonist in the treatment of parkinsonism

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970521-X

7 January 2021

Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970521-X

7 January 2021

Both short- and long-acting D-1/D-2 dopamine agonists induce less dyskinesia than L-DOPA in the MPTP-lesioned common marmoset (Callithrix jacchus).

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970521-X

7 January 2021

Nondopaminergic mechanisms in levodopa-induced dyskinesia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970521-X

7 January 2021

A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970521-X

7 January 2021

10.1016/S1474-4422(06)70521-X

Identifiers

DOI

1 reference

14 August 2017

1 reference

PubMed ID

16857573